Skip to content

AXIM BIOTECHNOLOGIES, INC.: 10-Q/A filed 2020-11-27

What AXIM BIOTECHNOLOGIES, INC. reported in its quarterly report amendment filed 2020-11-27 (fiscal Q3 2020): 36 published measures, 110 facts as tagged in accession 0001078782-20-000923.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2020-11-27
Fiscal period
fiscal Q3 2020
Accession
0001078782-20-000923 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AXIM BIOTECHNOLOGIES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-3012,128,937USD
At 2019-12-311,691,899USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-309,841,440USD
At 2019-12-318,452,296USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-301,157,239USD
At 2019-12-31511,630USD
At 2019-09-301,167,417USD
At 2018-12-311,805,627USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,905,567USD92
2020-01-01 to 2020-09-30-4,013,324USD274
2019-07-01 to 2019-09-30-863,618USD92
2019-01-01 to 2019-09-30-5,011,446USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-2,592,166USD274
2019-01-01 to 2019-09-30-3,629,911USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-303,244,130USD274
2019-01-01 to 2019-09-302,814,208USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-6,355USD274
2019-01-01 to 2019-09-30177,493USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-39,453,365USD
At 2019-12-31-35,440,042USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-0.02USD/shares92
2020-01-01 to 2020-09-30-0.04USD/shares274
2019-07-01 to 2019-09-30-0.01USD/shares92
2019-01-01 to 2019-09-30-0.08USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-0.02USD/shares92
2020-01-01 to 2020-09-30-0.04USD/shares274
2019-07-01 to 2019-09-30-0.01USD/shares92
2019-01-01 to 2019-09-30-0.08USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-3098,444USD
At 2019-12-312,237USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-09-30779,029USD274
2019-01-01 to 2019-09-301,615,000USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,298,778USD92
2020-01-01 to 2020-09-30-2,688,348USD274
2019-07-01 to 2019-09-30-483,672USD92
2019-01-01 to 2019-09-30-2,540,353USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-301,615,517USD
At 2019-12-311,639,128USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-07-01 to 2020-09-3073,268USD92
2020-01-01 to 2020-09-30179,344USD274
2019-07-01 to 2019-09-3049,304USD92
2019-01-01 to 2019-09-30147,529USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-301,599,654USD
At 2019-12-313,395,431USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2020-09-302,458,233USD
At 2019-12-310USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,298,778USD92
2020-01-01 to 2020-09-302,688,348USD274
2019-07-01 to 2019-09-30483,672USD92
2019-01-01 to 2019-09-302,540,353USD273

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,184,267USD92
2020-01-01 to 2020-09-302,442,420USD274
2019-07-01 to 2019-09-30482,833USD92
2019-01-01 to 2019-09-302,537,836USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-30109,139USD92
2020-01-01 to 2020-09-30235,431USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-30125,196,970shares
At 2019-12-3164,854,539shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-3041,593,293USD
At 2019-12-3128,623,060USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2020-09-302,287,497USD
At 2020-06-30999,105USD
At 2020-03-31-361,712USD
At 2019-12-31-6,760,397USD
At 2019-09-30-6,177,638USD
At 2019-06-30-6,160,833USD
At 2019-03-31-5,286,684USD
At 2018-12-31-6,081,819USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-09-30143,703USD
At 2019-12-310USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-09-30123,632USD
At 2019-12-3116,780USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-09-3025,188USD
At 2019-12-3114,543USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-2,291,804USD92
2020-01-01 to 2020-09-30-4,042,468USD274
2019-07-01 to 2019-09-30-168,666USD92
2019-01-01 to 2019-09-30-2,222,497USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,905,567USD92
2020-01-01 to 2020-09-30-4,013,324USD274
2019-07-01 to 2019-09-30-863,618USD92
2019-01-01 to 2019-09-30-5,011,446USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-300USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-09-3010,496USD274
2019-01-01 to 2019-09-302,517USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-993,026USD92
2020-01-01 to 2020-09-30-1,354,120USD274
2019-07-01 to 2019-09-30315,006USD92
2019-01-01 to 2019-09-30317,856USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-300USD273

Inspect the source

Entity
AXIM BIOTECHNOLOGIES, INC. / CIK 0001514946
Captured
2026-09-20T09:13:30.666Z
SEC response SHA-256
5755093e2dfb1c20119737eacb251a5ef040e09cdc537c89d6edf9272249749e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001514946.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))